All News

The supplements were also linked to improvements in pain and disease activity markers.

Sepiapterin treatment allowed patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living with phenylketonuria.

Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

Patients with ASCVD face increased cardiovascular risks post revascularization, yet many miss timely LDL-C testing and treatment, highlighting critical care gaps.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

FDA approves lonapegsomatropin for once-weekly treatment of growth hormone deficiency, offering a promising alternative for improved patient adherence and outcomes.

George Wang discusses the widespread financial barriers patients with cancer face, the environmental and economic toll of oncology drug waste, and how pharmacist-supported medication donation programs can safely and legally redistribute surplus cancer treatments to patients in need.

Independent specialty pharmacies face growing financial and operational pressures from rising drug costs, restrictive PBM contracts, and regulatory complexity, prompting many to explore strategic partnerships or sales as a means to sustain clinical excellence, preserve autonomy, and ensure long-term viability in an increasingly challenging health care environment.

Explore pharmacy policy updates and insights for July 2025.

Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.

Many factors contribute to vaccine skepticism, including trust, convenience, and fear.

VMAT2 inhibitors can improve movement symptoms.

Joel Stanley of Ajna Biosciences reflects on the regulatory challenges surrounding MDMA-assisted therapy, outlines lessons for future psychedelic drug trials, and emphasizes the importance of scientific rigor, interdisciplinary infrastructure, and the evolving role of pharmacists in ensuring safe clinical integration.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

Essential tips on prenatal vitamins, ovulation kits, pregnancy tests, and emergency contraception for effective family planning and pregnancy preparation.

There is no established routine monitoring schedule, but close observation is critical.

Targeting BRD4 with BET inhibitors shows promise in reversing immune suppression by myeloid-derived suppressor cells in chronic lymphocytic leukemia.

With cuts to the Department of Health and Human Services incoming, efforts to research, surveil, and prevent infections of Clostridioides difficile could be derailed.

Namrata Shah, MD, discusses the groundbreaking efficacy and patient-centered potential of twice-yearly lenacapavir for HIV preexposure prophylaxis (PrEP), supported by pivotal data from the PURPOSE trials.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Insights from the American Diabetes Association 85th Scientific Sessions.

Conversely, Medicaid enrollees experienced widening gaps of pneumococcal vaccination uptake, likely driven by socioeconomic obstacles.

Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children.

GLP-1 receptor agonists show promise in alleviating PCOS symptoms, including weight loss and menstrual regulation, despite needing further research.

Ochsner partners with Latent Health to utilize clinical artificial intelligence (AI), speeding prior authorizations, improving pharmacy efficiency, and increasing patient access to medications.

Pharmacy technicians evolve into vital health care roles, enhancing patient care and operational efficiency through structured career advancement pathways.

UPMC Health Plan enhances COPD care through personalized treatment, telemedicine, and comprehensive support, ensuring optimal patient outcomes and adherence.